Susceptibility to levofloxacin of clinical isolates of bacteria from intensive care and haematology/oncology patients in Switzerland: A multicentre study

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue SUPPL. C, 1999, Pages 51-54

  Siegrist, Hans H ^a,b   Nepa, Mary Claude ^a   Jacquet, Alain ^a  

^a Inst Neuchatelois de Microbiologie   (Switzerland)

^b Inst Neuchatelois de Microbiologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; CITROBACTER FREUNDII; CITROBACTER KOSERI; CLINICAL TRIAL; CONFERENCE PAPER; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS; HEMATOLOGY; HUMAN; INTENSIVE CARE; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MORGANELLA MORGANII; MULTICENTER STUDY; ONCOLOGY; PROTEUS MIRABILIS; PROTEUS VULGARIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; SERRATIA; SKIN INJURY; STAPHYLOCOCCUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; BACTERIA; HEMATOLOGIC DISEASES; HOSPITAL UNITS; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; NEOPLASMS; OFLOXACIN; PROSPECTIVE STUDIES; SWITZERLAND;

EID: 0032974129     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Baquero, F. (1996). Epidemiology and management of penicillin-resistant pneumococci. Current Opinion in Infectious Diseases 9, 372-9.
2. Doern, G. V. (1995). Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. American Journal of Medicine 99, Suppl. 6B, 3-7S.
3. Jacoby, G. A. (1994). Prevalence and resistance mechanisms of common bacterial respiratory pathogens. Clinical Infectious Diseases 18, 951-7.
4. Barry, A. L., Fuchs, P. C., Allen, S. D., Brown, S. D., Jorgensen, J. H. & Tenover, F. C. (1996). In-vitro susceptibility of Streptococcus pneumoniae to the D-and L-isomers of ofloxacin: interpretive criteria and quality control limits. Antimicrobial Chemotherapy 37, 365-9.
5. Davis, R. & Bryson, H. M. (1994). Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47, 677-700.
6. DeAbate, C. A., Russell, M., McElvaine, P., Faris, H., Upchurch, J., Fowler, C. L. et al. (1997). Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respiratory Care 42, 206-13.
7. Eliopoulos, G. M., Wennersten, C. B. & Moellering, R. C. (1996). Comparative in vitro activity of levofloxacin and ofloxacin against Gram-positive bacteria. Diagnostic Microbiology and Infectious Disease 25, 35-41.
8. File, T. M., Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R. R. et al. (1997). A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriazone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 41, 1965-72.
9. Fu, K. P., Lafredo, S. C., Foleno, B., Isaacson, D. M., Barrett, J. F., Tobia, A. J. et al. (1992). In vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin), an optically active ofloxacin. Antimicrobial Agents and Chemotherapy 36, 860-6.
10. Rastogi, N., Goh, K. S., Bryskier, A. & Devallois, A. (1996). Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin and clofazimine. Antimicrobial Agents and Chemotherapy 40, 2483-7.
11. Yamane, N., Jones, R. N., Frei, R., Hoban, D. J., Pignatari, A. C. & Marco, F. (1994). Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. Journal of Chemotherapy 6, 83-91.
12. National Committee for Clinical Laboratory Standards. (1994). Performance Standards for Antimicrobial Disk Susceptibility Tests-Sixth Edition: Approved Standard M2-A6. NCCLS, Wayne, PA.
13. von Eiff, C. & Peters, G. (1996). In-vitro activity of ofloxacin, levofloxacin, and D-ofloxacin against staphylococci. Journal of Antimicrobial Chemotherapy 38, 259-63.
14. Gootz, T. D. & Brighty, K. E. (1996). Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects. Medicinal Research Reviews 16, 433-86.
15. Biedenbach, D. J. & Jones, R. N. (1996). The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagnostic Microbiology and Infectious Disease 25, 47-51.
16. Fu, K. P., Lafredo, S. C. & Foleno, R. W. (1993). Induction of resistance of Streptococcus pneumoniae to levofloxacin, ciprofloxacin, and norfloxacin in vitro. Drugs 46, Suppl. 3, 198.
17. Rubinstein E., Carbon, C., Rangaraj, M., Santos, J. I., Thys, J. P. & Veyssier, P. (1998). Lower respiratory tract infections: etiology, current treatment, and experience with fluoroquinolones. Clinical Microbiology and Infection 4, Suppl. 2, S42-50.